[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100176122":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":45,"centralContacts":11,"locations":49,"responsibleParty":61,"collaborators":11,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":11,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment A, Cohort 1","EXPERIMENTAL",null,[13],"Drug: fesoterodine fumarate",{"label":15,"type":10,"description":11,"interventionNames":16},"Treatment B, Cohort 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Treatment C, Cohort 1",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Treatment D, Cohort 2",[13],{"label":24,"type":25,"description":11,"interventionNames":26},"Treatment E, Cohort 1 and\u002For Cohort 2","ACTIVE_COMPARATOR",[13],[28,33,36,39,42],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","fesoterodine fumarate","One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose",[9],{"type":29,"name":30,"description":34,"armGroupLabels":35,"otherNames":11},"One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose",[15],{"type":29,"name":30,"description":37,"armGroupLabels":38,"otherNames":11},"One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose",[18],{"type":29,"name":30,"description":40,"armGroupLabels":41,"otherNames":11},"One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose",[21],{"type":29,"name":30,"description":43,"armGroupLabels":44,"otherNames":11},"one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose",[24],[46],{"name":47,"affiliation":5,"role":48},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[50],{"facility":51,"status":11,"city":52,"state":52,"zip":53,"country":52,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":11},"Pfizer Investigational Site","Singapore","188770","SG",{"type":56,"coordinates":57},"Point",[58,59],103.85007,1.28967,{"lat":59,"lon":58},{"type":62,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100176122","phase-1-a-study-to-estimate-the-effects-of-food-on-drug-fesoterodine-fumarate-and-the-pharmacokinetics-of-5-hydroxymethyl-tolterodine-5-hmt-in-healthy-volunteers-100176122",false,"NCT01566760","A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers","Open-Label, Single-Dose, Randomized, Crossover Study To Estimate The Effects Of Food On The Pharmacokinetics Of Two Fesoterodine Sustained-Release Beads-In-Capsule Formulations And To Estimate The Relative Bioavailability Of One Or Both Formulations Compared To Commercial Tablet Formulation In Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy male and\u002For female subjects between 21 and 55 years of age(inclusive).\n\nExclusion Criteria:\n\n* Evidence or history of clinically significant disease.\n* Evidence or history of urologic disease (benign prostate hyperplasia, recurrent urinary tract infections, urinary retention, etc.).",true,"ALL","21 Years","55 Years",{"count":75,"type":76},24,"ACTUAL","INTERVENTIONAL",[79],"PHASE1","This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 2-cohort, 3-period study to characterize the pharmacokinetics (process by which drug fesoterodine is absorbed, distributed, metabolized, and eliminated by the body) and the effects of food on the pharmacokinetics of the drug. This study will take place over approximately 8 weeks and will consist of a screening visit to determine eligibility for the study, and 2- or 3-period treatment phase for each cohort.",[82],"Urinary Bladder, Overactive",[84,85,86,87,88,89],"food effect","bioavailability","pharmacokinetics","fesoterodine","5-hydroxymethyl tolterodine","treatment of overactive bladder","COMPLETED","2016-08-17",{"date":93,"type":94},"2016-08-19","ESTIMATED",{"date":96,"type":11},"2012-05",{"date":98,"type":76},"2012-07",{"name":5,"class":6},1]